{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T09:56:26Z","timestamp":1764842186772,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T00:00:00Z","timestamp":1548633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T00:00:00Z","timestamp":1548633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2019,3,1]]},"DOI":"10.1007\/s12325-019-0874-6","type":"journal-article","created":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T16:22:25Z","timestamp":1548692545000},"page":"670-683","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Prospective Observational Cohort Study to Describe the Use of Panitumumab in Combination with Chemotherapy in Real-World Clinical Practice for Patients with Wild-Type RAS mCRC"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4536-9955","authenticated-orcid":false,"given":"Holger","family":"Hebart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0216-3861","authenticated-orcid":false,"given":"Michael","family":"Kiehl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7635-9103","authenticated-orcid":false,"given":"Jiri","family":"Tomasek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7742-1968","authenticated-orcid":false,"given":"Tibor","family":"Csoszi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reija","family":"Koukakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Kafatos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Kuhn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja","family":"Bjorklof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaston","family":"Demonty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Buchler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,28]]},"reference":[{"key":"874_CR1","unstructured":"Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11. 2013. http:\/\/globocan.iarc.fr. Accessed 15 Jan 2018."},{"issue":"6","key":"874_CR2","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s11864-001-0068-7","volume":"2","author":"HL Kindler","year":"2001","unstructured":"Kindler HL, Shulman KL. Metastatic colorectal cancer. Curr Treat Options Oncol. 2001;2(6):459\u201371.","journal-title":"Curr Treat Options Oncol"},{"key":"874_CR3","first-page":"149","volume-title":"Colorectal and anal cancers. Cancer management: a multidisciplinary approach","author":"R Pazdur","year":"1999","unstructured":"Pazdur R, Coia L, Wagman LD, Ayoub JP. Colorectal and anal cancers. Cancer management: a multidisciplinary approach. Melville: PRR; 1999. p. 149\u201375."},{"issue":"8","key":"874_CR4","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","volume":"27","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386\u2013422.","journal-title":"Ann Oncol"},{"issue":"1","key":"874_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/CAD.0b013e32800feecb","volume":"18","author":"M Cohenuram","year":"2007","unstructured":"Cohenuram M, Saif MW. Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs. 2007;18(1):7\u201315.","journal-title":"Anticancer Drugs"},{"issue":"4","key":"874_CR6","doi-asserted-by":"publisher","first-page":"373","DOI":"10.2217\/fon.12.20","volume":"8","author":"G Argiles","year":"2012","unstructured":"Argiles G, Dienstmann R, Elez E, Tabernero J. Panitumumab: a summary of clinical development in colorectal cancer and future directions. Future Oncol. 2012;8(4):373\u201389.","journal-title":"Future Oncol"},{"key":"874_CR7","unstructured":"European Medicines Agency. Vectibix\u00ae (panitumumab) summary of product characteristics. 2016. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000741\/WC500047710.pdf. Accessed 15 Jan 2018."},{"key":"874_CR8","unstructured":"European Medicines Agency. Vectibix: EPAR\u2014scientific discussion. 2007. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Scientific_Discussion\/human\/000741\/WC500047707.pdf. Accessed 6 Mar 2018."},{"issue":"7","key":"874_CR9","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1002\/cncr.24088","volume":"115","author":"M Peeters","year":"2009","unstructured":"Peeters M, Siena S, Van Cutsem E, et al. Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer. 2009;115(7):1544\u201354.","journal-title":"Cancer"},{"issue":"10","key":"874_CR10","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","volume":"26","author":"RG Amado","year":"2008","unstructured":"Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(10):1626\u201334.","journal-title":"J Clin Oncol"},{"issue":"31","key":"874_CR11","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","volume":"28","author":"JY Douillard","year":"2010","unstructured":"Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28(31):4697\u2013705.","journal-title":"J Clin Oncol"},{"issue":"31","key":"874_CR12","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1200\/JCO.2009.27.6055","volume":"28","author":"M Peeters","year":"2010","unstructured":"Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28(31):4706\u201313.","journal-title":"J Clin Oncol"},{"issue":"3","key":"874_CR13","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.clcc.2011.03.022","volume":"10","author":"AL Cohn","year":"2011","unstructured":"Cohn AL, Shumaker GC, Khandelwal P, et al. An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2011;10(3):171\u20137.","journal-title":"Clin Colorectal Cancer"},{"issue":"4","key":"874_CR14","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.clcc.2011.06.004","volume":"10","author":"EP Mitchell","year":"2011","unstructured":"Mitchell EP, Piperdi B, Lacouture ME, et al. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (skin toxicity evaluation protocol with panitumumab) by KRAS status. Clin Colorectal Cancer. 2011;10(4):333\u20139.","journal-title":"Clin Colorectal Cancer"},{"issue":"1","key":"874_CR15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00432-011-1061-6","volume":"138","author":"CH Kohne","year":"2012","unstructured":"Kohne CH, Hofheinz R, Mineur L, et al. First-line panitumumab plus irinotecan\/5-fluorouracil\/leucovorin treatment in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol. 2012;138(1):65\u201372.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"874_CR16","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","volume":"369","author":"JY Douillard","year":"2013","unstructured":"Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369(11):1023\u201334.","journal-title":"N Engl J Med"},{"issue":"1","key":"874_CR17","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1177\/1756283X13498660","volume":"7","author":"CM Hocking","year":"2014","unstructured":"Hocking CM, Price TJ. Panitumumab in the management of patients with KRAS wild-type metastatic colorectal cancer. Ther Adv Gastroenterol. 2014;7(1):20\u201337.","journal-title":"Ther Adv Gastroenterol"},{"key":"874_CR18","unstructured":"European Medicines Agency. Vectibix: Procedural steps taken and scientific information after the authorisation. 2017. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Procedural_steps_taken_and_scientific_information_after_authorisation\/human\/000741\/WC500047709.pdf. Accessed 3 July 2017."},{"key":"874_CR19","doi-asserted-by":"crossref","unstructured":"Tejpar S, Stintzing S, Ciardiello F, et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol. 2017;3(2):194\u2013201.","DOI":"10.1001\/jamaoncol.2016.3797"},{"issue":"21","key":"874_CR20","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1200\/JCO.2013.53.2473","volume":"32","author":"LS Schwartzberg","year":"2014","unstructured":"Schwartzberg LS, Rivera F, Karthaus M, et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol. 2014;32(21):2240\u20137.","journal-title":"J Clin Oncol"},{"issue":"8","key":"874_CR21","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s00384-017-2800-1","volume":"32","author":"F Rivera","year":"2017","unstructured":"Rivera F, Karthaus M, Hecht JR, et al. Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma. Int J Colorectal Dis. 2017;32(8):1179\u201390.","journal-title":"Int J Colorectal Dis"},{"issue":"7","key":"874_CR22","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/annonc\/mdu141","volume":"25","author":"JY Douillard","year":"2014","unstructured":"Douillard JY, Siena S, Cassidy J, et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol. 2014;25(7):1346\u201355.","journal-title":"Ann Oncol"},{"issue":"24","key":"874_CR23","doi-asserted-by":"publisher","first-page":"5469","DOI":"10.1158\/1078-0432.CCR-15-0526","volume":"21","author":"M Peeters","year":"2015","unstructured":"Peeters M, Oliner KS, Price TJ, et al. Analysis of KRAS\/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer. Clin Cancer Res. 2015;21(24):5469\u201379.","journal-title":"Clin Cancer Res"},{"key":"874_CR24","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2147\/CMAR.S86796","volume":"7","author":"R Lakomy","year":"2015","unstructured":"Lakomy R, Rogowski W, Piko B, Mihaylova Z, Pritzova E, Kvocekova L. Prospective noninterventional study on the use of panitumumab monotherapy in patients with recurrent or progressive colorectal cancer: the VECTIS study. Cancer Manage Res. 2015;7:311\u20138.","journal-title":"Cancer Manage Res"},{"issue":"suppl 4","key":"874_CR25","doi-asserted-by":"publisher","first-page":"abstr 550","DOI":"10.1200\/jco.2013.31.4_suppl.550","volume":"31","author":"CA Lerchenmueller","year":"2013","unstructured":"Lerchenmueller CA, Groschek M, Kroening H, et al. Panitumumab in patients with chemorefractory metastatic colorectal cancer: final analysis from a community-based, observational study (VECTOR) in Germany. J Clin Oncol. 2013;31(suppl 4):abstr 550.","journal-title":"J Clin Oncol"},{"issue":"10","key":"874_CR26","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.ejca.2015.03.026","volume":"51","author":"JY Douillard","year":"2015","unstructured":"Douillard JY, Siena S, Peeters M, Koukakis R, Terwey JH, Tabernero J. Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer. Eur J Cancer. 2015;51(10):1231\u201342.","journal-title":"Eur J Cancer"},{"issue":"62","key":"874_CR27","doi-asserted-by":"publisher","first-page":"105061","DOI":"10.18632\/oncotarget.21249","volume":"8","author":"M Kripp","year":"2017","unstructured":"Kripp M, Prasnikar N, Vehling-Kaiser U, et al. AIO LQ-0110: a randomized phase II trial comparing oral doxycycline versus local administration of erythromycin as preemptive treatment strategies of panitumumab-mediated skin toxicity in patients with metastatic colorectal cancer. Oncotarget. 2017;8(62):105061\u201371.","journal-title":"Oncotarget"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-0874-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-019-0874-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-0874-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T07:15:09Z","timestamp":1713597309000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-019-0874-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,28]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3,1]]}},"alternative-id":["874"],"URL":"https:\/\/doi.org\/10.1007\/s12325-019-0874-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2019,1,28]]},"assertion":[{"value":"14 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}